Safety,tolerability,efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus

Abstract

We aimed to evaluate the pharmacodynamics, efficacy, safety and tolerability of the JAK1 inhibitor GSK2586184 in adults with systemic lupus erythematosus (SLE). In this adaptive, randomized, double-blind, placebo-controlled study, patients received oral GSK2586184 50–400 mg, or placebo twice daily for 12 weeks. Primary endpoints included interferon-mediated messenger RNA transcription over time, changes in Safety of Estrogen in Lupus National Assessment-SLE Disease Activity Index score, and number/severity of adverse events. A pre-specified interim analysis was performed when ≥ 5 patients per group completed 2 weeks of treatment. In total, 84–92% of patients were high baseline expressors of the interferon transcriptional biomarkers evaluated. At interim analysis, GSK2586184 showed no significant effect on mean interferon transcriptional biomarker expression (all panels). The study was declared futile and recruitment was halted at 50 patients. Shortly thereafter, significant safety data were identified, including elevated liver enzymes in six patients (one confirmed and one suspected case of Drug Reaction with Eosinophilia and Systemic Symptoms), leading to immediate dosing cessation. Safety of Estrogen in Lupus National Assessment-SLE Disease Activity Index scores were not analysed due to the small number of patients completing the study. The study futility and safety data described for GSK2586184 do not support further evaluation in patients with SLE.

Study identifiers: GSK Study JAK115919; ClinicalTrials.gov identifier: NCT01777256.

Keywords

DRESS syndrome interferon JAK1 inhibitor systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Laurence

Pesu

Silvennoinen

O’Shea

. JAK kinases in health and disease: An update. Open Rheumatol J 2012; 6: 232–244.

Sohn

Barrett

Van Abbema

. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 2013; 191: 2205–2216.

Niewold

Clark

Salloum

Poole

. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol 2010; 948364.

Yao

Richman

Higgs

. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785–1796.

Yao

Richman

Morehouse

. Type I interferon: Potential therapeutic target for psoriasis? PLoS One 2008; 3: e2737–e2737.

Baechler

Batliwalla

Karypis

. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci 2003; 100: 2610–2615.

Beadling

Guschin

Witthuhn

. Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. EMBO J 1994; 13: 5605–5615.

Silvennoinen

Ihle

Schlessinger

Levy

. Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature 1993; 366: 583–585.

Seavey

Dobrzanski

. The many faces of Janus kinase. Biochem Pharmacol 2012; 83: 1136–1145.

10.

Van Rompaey

Galien

van der Aar

. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013; 191: 3568–3577.

11.

Verstovsek

Mesa

Gotlib

. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.

12.

Kontzias

Laurence

Gadina

O’Shea

. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep 2012; 4: 5–5.

13.

XELJANZ; Highlights of prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=959 (2012, accessed September 2015).

14.

Neubauer

Cumano

Müller

Huffstadt

Pfeffer

. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93: 397–409.

15.

Grisouard

Hao-Shen

Dirnhofer

Wagner

Skoda

. Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica 2014; 99: e52–e54.

16.

Haan

Rolvering

Raulf

. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem Biol 2011; 18: 314–323.

17.

GlaxoSmithKline. GSK2586184 investigator’s brochure. GlaxoSmithKline document number 2011N131059_01. 2013.

18.

Ludbrook

Hicks

Hanrott

. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled Phase 2 a study. Br J Dermatol, Epub ahead of print 2016. DOI: 10.1111/bjd.14399.

19.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: Guideline for good clinical practice E6(1). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (1996, accessed September 2015).

20.

World Medical Association. WMA Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/17c.pdf (2008, accessed September 2015).

21.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

22.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

23.

Petri

Kim

Kalunian

. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

24.

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry. Drug-induced liver injury: Premarketing clinical evaluation. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf (2009, accessed September 2015).

25.

Skare

Ferri

Santos

. Systemic lupus erythematosus activity and beta two microglobulin levels. Sao Paulo Med J 2014; 132: 239–242.

26.

van Vollenhoven

Layton

Kahl

. Severe, unexpected drug reactions and reversible liver function abnormalities in subjects with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus 2015; 24: 648–649.

27.

Kardaun

Sidoroff

Valeyrie-Allanore

. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609–611.

28.

US Food and Drug Administration. FDA background materials for new drug application 203214: tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had inadequate response to one or more disease modifying anti-rheumatic drugs. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960 (2012, accessed September 2015).

29.

Kanny

Renaudin

J-M

Lecompte

Moneret-Vautrin

. Chloroquine hypersensitivity syndrome. Eur J Intern Med 2002; 13: 75–76.

30.

Volpe

Marchetta

Caramaschi

Biasi

Bambara

Arcaro

. Hydroxychloroquine-induced DRESS syndrome. Clin Rheum 2008; 27: 537–539.

31.

Picard

Janela

Descamps

. Drug reaction with eosinophilia and systemic symptoms (DRESS): A multiorgan antiviral T cell response. Sci Transl Med 2010; 2: 46ra62–46ra62.

32.

Kremer

Bloom

Breedveld

. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895–1905.

33.

Riese

Krishnaswami

Kremer

. Inhibition of JAK kinases in patients with rheumatoid arthritis: Scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010; 24: 513–526.

34.

McInnes

Thompson

Giles

. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015; 74: 694–702.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB

0.06 MB

0.08 MB